Description
BML-277 is an arylbenzimidazole inhibitor of checkpoint kinase 2 (CHK2). This compound displays cytoprotective activity, protecting CD4+ and CD8+ T cells against radiation-induced apoptosis.
BML-277 is an arylbenzimidazole inhibitor of checkpoint kinase 2 (CHK2). This compound displays cytoprotective activity, protecting CD4+ and CD8+ T cells against radiation-induced apoptosis.
Cas No. | 516480-79-8 |
---|---|
Purity | ≥98% |
Formula | C20H14ClN3O2 |
Formula Wt. | 363.80 |
IUPAC Name | 2-[4-(4-Chlorophenoxy)phenyl]-1H-benzimidazole-5-carboxamide |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
Info Sheet | B5044 Info Sheet PDF |
---|
Arienti KL, Brunmark A, Axe FU, et al. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem. 2005 Mar 24;48(6):1873-85. PMID: 15771432.